Tonix Pharmaceuticals Holding (TNXP) Operating Income (2011 - 2026)

Tonix Pharmaceuticals Holding has reported Operating Income for 16 years, with the latest figure at -$42.5 million in Q2 2026.

• On a quarterly basis, Operating Income fell 50.32% year-over-year to -$42.5 million in Q2 2026; TTM through Jun 2026 was -$165.4 million, a 100.8% decrease from a year earlier, with the FY2025 full-year figure at -$125.7 million, up 8.05% from the prior year.
• Operating Income was -$42.5 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from -$41.5 million in the prior quarter.
• The five-year high for Operating Income was -$15.6 million in Q3 2024, with the low at -$77.3 million in Q2 2024.
• Average Operating Income over 5 years is -$32.1 million, with a median of -$28.6 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Income slumped 166.59% in 2024, then soared 63.4% in 2025.
• Over 5 years, Operating Income stood at -$32.7 million in 2022, then rose by 16.5% to -$27.3 million in 2023, then rose by 17.74% to -$22.5 million in 2024, then sank by 114.8% to -$48.3 million in 2025, then grew by 11.91% to -$42.5 million in 2026.
• The last three Operating Income figures came in at -$42.5 million (Q2 2026), -$41.5 million (Q1 2026), and -$48.3 million (Q4 2025), per Business Quant data.